Chk2 is a transducer of DNA damage signals and a tumour suppressor whose germ-line mutations predispose to diverse tumour types. Unlike its downstream targets such as the p53 tumour suppressor, the expression patterns of Chk2 in tissues and tumours remain unknown. As DNA breaks occur commonly during gametogenesis, and p53 is wild-type and overexpressed in testicular cancer, we examined abundance and localisation of the Chk2 protein during normal development of human testes, and at various stages of germ-cell tumour (GCT) pathogenesis. Our results show that Chk2 is abundant in foetal germ cells and adult spermatogonia, yet only weakly expressed or lacking during the meiotic and later stages of spermatogenesis. High levels of Chk2 are detected in the majority of GCTs including all preinvasive carcinoma-in-situ lesions, contrary to variable expression and even lack of Chk2 in subsets of invasive GCTs and some teratoma structures, respectively. Together with our analyses of cell culture models, these results indicate that downmodulation or lack of Chk2 is not simply attributable to quiescence or dierentiation, they suggest a role for Chk2 in mitotic rather than meiotic divisions, support the concept of foetal origin of GCTs, and have implications for protein-based screening for tumour-associated aberrations of Chk2. Oncogene (2001) 20, 5897 ± 5902.
Transmission of intact genetic information among generations of cells during gametogenesis, embryonic development, as well as tissue renewal in adulthood rely on a network of cell-cycle checkpoint pathways which monitor the genome and respond to DNA damage by cell cycle inhibition, stimulation of DNA repair, or induction of apoptosis to eliminate potentially hazardous, genetically altered cells (Zhou and Elledge, 2000) . Defects in these DNA damage checkpoint cascades may undermine genomic integrity and contribute to oncogenesis, and key components of the cell cycle checkpoint circuitry qualify as tumour suppressors, including p53 (May and May, 1999; Vogelstein et al., 2000) , BRCA1 (Scully and Livingston, 2000) , ATM (Rotman and Shiloh, 1999) , or the recently identi®ed Chk2/Cds1 (Chk2) protein kinase, the human homologue of the Saccharomyces cerevisiae RAD53 and Schizosaccharomyces pombe Cds1 DNA damage-activated checkpoint kinases (Matsuoka et al., 1998; Zhou and Elledge, 2000) . Upon exposure to genotoxic insults which cause double-strand DNA breaks (DSBs), Chk2 becomes activated by the upstream ATM kinase and then propagates the signal via phosphorylating substrates such as BRCA1 (Lee et al., 2000) , Cdc25A (Falck et al., 2001) , or p53 (Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 2000) . The link between p53 and Chk2 in a common biochemical pathway is further supported by genetic evidence, through identi®cation of mutations in the Chk2 gene in a subset of Li-Fraumeni syndrome families who do not harbour mutations in p53, previously shown to predispose to this highly cancer-prone condition (Bell et al., 1999) .
Despite its emerging roles as a tumour suppressor, mediator of the G1/S, intra-S, and G2/M-phase cellcycle checkpoints, and stimulator of DNA repair, Chk2 biology and pathology remain relatively unexplored, and there is no data on the abundance, localization, or cell-type speci®city of the Chk2 protein in human tissues and tumours. To initiate studies of Chk2 in diverse organs and tumour types, we raised two mouse monoclonal antibodies against distinct epitopes of Chk2, and applied these as probes here to analyse Chk2 in human cultured cells, testicular tissues at various stages of development, and a range of germ-cell tumours. The reasons which led us to choose spermatogenesis and testicular cancer to study Chk2 include: (i) occurrence in the same tissue of both mitotic and meiotic cell cycles; (ii) high frequency of programmed DNA strand breaks as an essential part of genetic recombination during meiosis; (iii) a wellde®ned, early-stage common precursor lesion: carcinoma in situ (Skakkebñk et al., 1987) ; (iv) several types of GCTs, including teratomas capable of dierentiating along diverse cellular lineages (Chaganti and Houlds-worth, 2000); (v) male infertility in mice de®cient in either ATM (Barlow et al., 1997) or BRCA1 (Cressman et al., 1999) operating upstream or downstream of Chk2 in somatic cells, respectively; (vi) a possibility that testicular cancer is part of the Li-Fraumeni syndrome (Hartley et al., 1989) ; and (vii) the facts that p53, the immediate downstream target of Chk2, is involved in monitoring spermatogenesis (Rotter et al., 1993; Schwartz et al., 1999) and it is commonly overexpressed but not mutated in human GCTs (Bartkova et al., 1991; Chaganti and Houldsworth, 2000; Lutzker and Levine, 1996) .
The speci®city of the two new MAbs for Chk2 was con®rmed by immunoblotting analysis of extracts from a panel of human cultured normal cell types and cancer cell lines (Figure 1a) , as well as the ability of these Mabs to recognize the in vitro transcribedtranslated Chk2, and the loss of reactivity upon preabsorption of these MAbs with recombinant Chk2 but not with other proteins. Immunohistochemical examination of a series of 31 archival specimens of normal human adult testes showed strong nuclear positivity of spermatogonia, giving rise to a characteristic pearl-like pattern of positive cells lining the inner periphery of the seminiferous tubules (Figure 1b,c) . In contrast to the mitotically proliferating spermatogonia, the Chk2 protein was only weakly expressed or undetectable in spermatocytes at dierent stages of meiosis, and virtually negative in the postmeiotic stages of spermatogenesis in the more central areas of the seminiferous tubules (Figure 1b,c) . Reminiscent of adult spermatogonia, high abundance of Chk2 was found also in their developmental precursors, the foetal and neonatal human gonocytes (Figure 1d ,e,f). These results demonstrate that in normal human testes, Chk2 is highly expressed in the mitotically proliferating germ cells throughout development, from foetal gonocytes to adult spermatogonia. Interestingly, the level of Chk2 is dramatically reduced during the meiotic stages of spermatogenesis, known to physiologically undergo a large number of DSBs. Since both the upstream activator of Chk2, the ATM kinase, and at least some of the substrates of ATM and Chk2, such as BRCA1 and p53, are expressed in meiotic spermatocytes (Schwartz et al., 1999; Zickler and Kleckner, 1999) , it is tempting to speculate that the downmodulation of Chk2 before meiosis might prevent potentially deleterious hyperactivation of Chk2 by the programmed DNA breaks during meiotic recombination. If expressed at high levels analogous to mitotically proliferating spermatogonia, Chk2 could stabilize p53 via its phosphorylation on serine 20 (Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 2000) and possibly induce inadequate apoptosis in response to physiological chromosome breaks and thus undermine spermatogenesis. This hypothesis appears consistent with the demonstrated role of a p53-dependent DNA damage checkpoint in controlling the quality of meiotic DNA in mice (Rotter et al., 1993; Schwartz et al., 1999) , as well as the fact that the moderately elevated expression of p53 in spermatocytes seems attributable to enhanced (Bartkova et al., 2000b) for Chk2 in normal human adult testis; c=seminiferous tubule centre; arrowheads: strongly positive spermatogonia (d,e) Foetal human testes at 17 and 28 weeks of gestation, respectively, and neonatal testis (f) with Chk2-positive gonocytes Shiloh, 1999) . To assess the Chk2 protein status in human GCTs, a series of carcinoma in situ (CIS) and diverse types of invasive GCTs including seminomas, embryonal carcinomas, teratomas and combined tumours were analysed by immunoperoxidase staining using the MAbs DCS-270 and DCS-273 ( Figure 2 , Table 1 ). Except for extremely rare Chk2-negative CIS cells (around 0.1% or fewer, documented in Figure 2b ), all preinvasive lesions showed highly abundant Chk2 expressed homogeneously in all CIS cells, contrasting with only very weakly positive Sertoli and other cells present in the same CIS-containing tubules (Figure 2a,b) . A considerably more variable expression of Chk2 was found among the invasive GCTs (Table 1) . Thus, only seven out of 20 seminomas, and none of 13 embryonal carcinomas showed the strong and almost homogeneous staining for Chk2 (Figure 2c Table 1 ). Teratomas displayed highly variable staining for Chk2 (Table 1) , typically very strong in glandular epithelial structures (Figure 2f ) and cysts of strati®ed squamous epithelium (Figure 2g) , with weaker staining seen in structures dierentiating along the muscle, adipocytic, and neuronal lineages, up to some completely negative structures composed of cartilage (Figure 2h and insert) or bone. Parallel staining of all sections for the proliferation marker Ki67 revealed no strict correlation of Chk2 expression with cycling cells, in that many apparently nonproliferating, dierentiated cells were moderately or even strongly positive for Chk2. Since immunoblots of tissue and tumour extracts consistently showed only one band of the size expected for Chk2 (Figure 3a) , and the two MAbs directed against distinct epitopes of Chk2 always showed consistent immunostaining patterns on parallel sections, we concluded that the immunohistochemical results including the positivity in non-proliferating cells re¯ect genuine Chk2.
To further elucidate the issue of Chk2 expression relative to teratoma proliferation and dierentiation, we employed the widely used dynamic model of the human NTera2/D1 teratocarcinoma, a cell line which can be induced by retinoic acid to dierentiate along the neuronal lineage (Andrews, 1984; Pleasure and Lee, 1993) . Time course immunoblotting experiments with exponentially growing and dierentiating NTera2/D1 cells (Figure 3b ) demonstrated that the abundance of Chk2 remained virtually constant throughout the 6-week experiment, well beyond the ®rst 2 weeks when the cells still proliferate, as documented by cyclin A levels ( Figure 3b ) and DNA synthesis (data not shown). The fact that high levels of Chk2 were detectable even in the enriched population of the quiescent, terminally dierentiated NTera2/D1 cells support the above conclusions based on the analysis of teratoma specimens in situ, and suggest that factors other than just proliferative status or degree of dierentiation control expression of this key mediator of DNA damage.
The intriguing contrast between the highly abundant Chk2 protein in the pre-invasive CIS lesions and lower or variable expression in subsets of invasive GCTs led us to consider the possibility that the protein level of Chk2 might re¯ect some aberrations of its expression and/or protein turnover in some human tumours. To address this issue in a model scenario amenable to experimental manipulation, we examined the abundance and subcellular localisation of Chk2 in 8 cancerderived cell lines with apparently wild-type Chk2 mRNA, compared with the HCT-15 colon cancer cell line, so far the only human tumour cell line with identi®ed mutation in the Chk2 gene, a missense mutation resulting in R145W substitution near the putative protein ± protein FHA domain of Chk2 (Bell et al., 1999) . While Chk2 immunostaining showed strong nuclear positivity in all cell lines harbouring (Falck et al., 2001) , and pre-treated (+) or not (7) with the proteasome inhibitor LLnL (Mailand et al., 2000) . Cdk7: stable control protein As the ®rst study of the Chk2 protein performed in any type of cancer, our present data show that immunohistochemical analysis of this emerging tumour suppressor is feasible in principle. In addition, the clear cell type-speci®c and stage-speci®c dierences of Chk2 abundance during testis development and spermatogenesis indicate a role for Chk2 in mitotically proliferating, rather than meiotic stages of male gametogenesis. Whether the weak expression seen in some spermatocytes re¯ects any residual function of Chk2 in meiosis, or rather traces of the long-lived Chk2 protein after its function in spermatogonia had been ful®lled, remains to be elucidated. In any case, the expression pattern of Chk2 detected here contrasts with that of Chk1, a partly functionally overlapping yet structurally unrelated checkpoint kinase (Zhou and Elledge, 2000) , which accumulates in late zygotene and pachytene spermatocytes and localizes to synapsed meiotic chromosomes, suggesting its possible involvement in monitoring the processing of meiotic recombination (Flaggs et al., 1997) . Our data reveal also another striking dierence between Chk2, abundant even in many nonproliferating and dierentiated cells (this study), and the Chk1 protein known to be absent in quiescent and G1 phase and only expressed in S/G2/M cells during mitotic cycles (Kaneko et al., 1999) . Finally, our results may have important implications for better understanding of human testicular germ-cell tumour biology, including their origin and response to therapy. First, the high abundance of Chk2 in foetal gonocytes and the pre-invasive carcinoma in situ lesions is consistent with the theory of origin of all human male GCTs from the primordial germ cells or gonocytes, rather than from spermatocytes (Grigor and Wylie, 1998; Skakkebñk et al., 1987) . Second, given the largely favourable response of testicular GCTs to radiotherapy and chemotherapy, and the fact that Chk2 is activated by DNA damage caused by such treatments and phosphorylates p53 which is almost invariably wild-type in testicular tumours (Chaganti and Houldsworth, 2000) , it would be important to examine whether the lower expression of Chk2, detected here in subsets of GCTs, might help identify cases potentially more resistant to therapy.
